Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Seizert Capital Partners LLC

Seizert Capital Partners LLC cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,775 shares of the biopharmaceutical company's stock after selling 6,185 shares during the period. Regeneron Pharmaceuticals accounts for 2.2% of Seizert Capital Partners LLC's portfolio, making the stock its 12th largest holding. Seizert Capital Partners LLC's holdings in Regeneron Pharmaceuticals were worth $48,121,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Brown Lisle Cummings Inc. increased its stake in shares of Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 10 shares in the last quarter. Sachetta LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Adirondack Trust Co. increased its stake in shares of Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company's stock worth $453,000 after purchasing an additional 10 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company's stock worth $955,000 after purchasing an additional 10 shares in the last quarter. Finally, Western Financial Corp CA increased its stake in shares of Regeneron Pharmaceuticals by 0.7% in the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company's stock worth $1,912,000 after purchasing an additional 12 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $25.70 during trading hours on Friday, hitting $756.81. 1,374,549 shares of the company were exchanged, compared to its average volume of 850,545. The stock has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52-week low of $753.69 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company's 50 day moving average price is $985.21 and its 200-day moving average price is $1,033.97.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 7.48% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a "buy" rating in a research note on Tuesday, July 23rd. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Finally, Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.